Cruzipain: An Update on its Potential as Chemotherapy Target against the Human Pathogen Trypanosoma cruzi

Author(s): M.H. Branquinha, S.S.C. Oliveira, L.S. Sangenito, C.L. Sodre, L.F. Kneipp, C.M. d’Avila-Levy, A.L.S. Santos.

Journal Name: Current Medicinal Chemistry

Volume 22 , Issue 18 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Chagas’ disease is one of the most impactful and prevalent neglected tropical diseases in the Americas, specially affecting the poor and underdeveloped areas in Latin America. Aggravating this scenario, the medicines used in the current chemotherapy are old, toxic and present a low efficacy to treat the chronic stage of this disease. In addition, resistant strains of Trypanosoma cruzi, the etiological agent, are frequently reported. So, there is an imperative requirement for novel chemotherapeutic options to treat this debilitating disease. In this context, peptidases have emerged as potential targets and, consequently, proteolytic inhibitors have confirmed to be valuable drugs against several human pathologies. In this line of thinking, T. cruzi produces a major multifunctional cysteine peptidase, named cruzipain, which directly and/or indirectly orchestrates several physiological and pathological processes, which culminate in a successful parasitic infection. Taken together, these findings point out that cruzipain is one of the most important targets for driving a chemotherapy approach against the human pathogen T. cruzi. The present review summarizes some of the recent advances and failures in this area, with particular emphasis on recently published studies.

Keywords: Chagas’ disease, Trypanosoma cruzi, human pathogen, neglected tropical disease, cysteine peptidases, cruzipain, proteolytic inhibitors, chemotherapy.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 22
ISSUE: 18
Year: 2015
Page: [2225 - 2235]
Pages: 11
DOI: 10.2174/0929867322666150521091652
Price: $58

Article Metrics

PDF: 21